Related Experiment Video
Updated: Jun 15, 2026
06:07
Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
Examining Braak's hypothesis by imaging Parkinson's disease
1MRC Clinical Sciences Centre and Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK. david.brooks@csc.mrc.ac.uk
Movement Disorders : Official Journal of the Movement Disorder Society
|February 27, 2010
Summary
Imaging reveals Parkinson's disease (PD) brain changes that don't fully align with the Braak staging of Lewy body pathology. This suggests selective neuronal vulnerability to synuclein aggregates in PD.
Area of Science:
- Neuroscience
- Medical Imaging
- Pathology
Background:
- Parkinson's disease (PD) is characterized by Lewy body pathology, typically described by Braak staging.
- Imaging techniques can detect in vivo changes in the brain related to PD.
Purpose of the Study:
- To compare in vivo imaging findings in Parkinson's disease (PD) patients and at-risk individuals with the predicted Braak staging.
- To investigate the relationship between imaging-detected brain dysfunction and Lewy body pathology progression.
Main Methods:
- Review of in vivo imaging studies (structural, metabolic, neurotransmitter binding) in symptomatic PD and at-risk subjects.
- Comparison of imaging data with established Braak staging of neuropathology.
Main Results:
- Imaging-detected brain dysfunction in PD is only partially consistent with the Braak staging's proposed progression.
- Discrepancies suggest that neuronal vulnerability in PD may not solely follow the Braak staging sequence.
Conclusions:
- The Braak staging model may not fully capture the in vivo progression of PD-related neural dysfunction.
- Selective vulnerability of neurons in specific brain regions to intracellular alpha-synuclein aggregates is likely a key factor in PD pathogenesis.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...